Gene test could match prostate cancer patients to better chemo
NCT ID NCT02955082
First seen Feb 04, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This study looks at whether men with a certain type of advanced prostate cancer (castration-resistant) who have inherited DNA repair gene mutations respond better to the chemotherapy drug carboplatin. Researchers will first screen participants for these genetic changes, then treat those with mutations using carboplatin. The goal is to see if the tumors shrink or PSA levels drop, which could pave the way for more personalized cancer care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE REFRACTORY PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Cancer Research and Royal Marsden Hospital
Sutton, Surrey, SM2 5PT, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin (chemotherapy drug)
What this could lead to
If successful, this could show that genetic testing helps identify which men with advanced prostate cancer will benefit from carboplatin, leading to more personalized treatment.
What could go wrong
This is a small, early-phase study (Phase 2) with only 305 participants. The results may not apply to all patients, and carboplatin can cause side effects like low blood counts and fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.